Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Brea
As much as 50% of patients treated with hormonotherapy (HT) for breast cancer (BC) suffer from osteoarticular pain during treatment. Secondary effects have become a real issue because of their consequences on the patients' quality of life, but also on treatment efficacy and survival when they induce dose reduction or p
| Condition(s) | Breast Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | As much as 50% of patients treated with hormonotherapy (HT) for breast cancer (BC) suffer from osteoarticular pain during treatment. Secondary effects have become a real issue because of their consequences on the patients' quality of life, but also on treatment efficacy and survival when they induce dose reduction or premature withdrawal of treatment. Additional medicines (acupuncture, hypnosis, yoga) have become more and more popular these last years. 48 to 80% of patients with BC eventually choose them. A review comparing efficacy of various therapies to decrease osteoarticular pain concludes to a highest efficacy of anti-inflammatory treatments, paracetamol and yoga. It thus appears innovative to complete this care with a patient educational project (PEP) in postural yoga instructed by |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years * Non metastatic breast cancer * Ongoing hormone therapy, with no treatment modification in the 30 days before inclusion * Osteoarticular and/or musculoskeletal pain due to HT ≥ 4 on the Numeric Pain Rating Scale (NPRS) * Previous treatment (surgery, chemotherapy or radiotherapy) ended at least 2 months before inclusion * Informed patient and signed informed consent received * Affiliation to a social security system Exclusion Criteria: * Chronic rhumatologic pain with specific care needed * Regular Yoga practice in the 3 months before inclusion * Contraindication or clinical state not allowing physical practice * Patient whose regular follow-up is initially impossible for psychological, family, social or geographical reasons, * Pregnant and breastfeedin |
| Ages | 18 Years to 99 Years |
| Sex | Female |
| Lead sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
| Locations | Libourne, Aquitaine, France; Montpellier, Herault, France; Nîmes, Herault, France; Vandœuvre-lès-Nancy, Meurthe-et-Moselle,, France; Bordeaux, New Aquitaine, France; Tosse, New Aquitaine, France (+1 more sites) |
| Start date | 2021-02-11 |
| NCT ID | NCT04457895 |
| Official listing | https://clinicaltrials.gov/study/NCT04457895 |